TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12476494

Group type: EXPERIMENTAL
Intervention: Fränkel function regulators
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Harvold activators
Number of subjects: 51

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 51
Study: 9084355

Group type: EXPERIMENTAL
Intervention: Audiovisual erotic stimulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with audiovisual erotic stimulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with distracting task
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Masturbation
Number of subjects: 17
Study: 8263331

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drains
Number of subjects: 200

Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 200
Study: 3979007

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.075 mg/kg three times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (10 mg/kg twice a day)
Number of subjects: 12
Study: 31509896

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fibular free flap reconstruction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pentoxifylline, Vitamin E, and sometimes a bisphosphonate
Number of subjects: 54
Study: 29708281

Group type: EXPERIMENTAL
Intervention: OBE022 (single ascending doses of 10, 30, 100, 300, 1000 or 1300 mg; multiple ascending doses of 100, 300 or 1000 mg day-1 for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OBE022
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26965178

Group type: EXPERIMENTAL
Intervention: CaHMB, vitamin D, and protein supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard postoperative nutrition
Number of subjects: 75
Study: 24708640

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg) and magnesium (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22374888

Group type: EXPERIMENTAL
Intervention: Gelfoam soaked with HA-CMC
Number of subjects: 287

Group type: COMPARATOR
Intervention: Gelfoam only (Control)
Number of subjects: 287
Study: 20346640

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enhanced Standard Care (Control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (CBT and Control)
Number of subjects: 51
Study: 18414367

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 50
Study: 16320092

Group type: EXPERIMENTAL
Intervention: Continuous-sound fMRI
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional fMRI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both scanning protocols
Number of subjects: 16
Study: 12893153

Group type: EXPERIMENTAL
Intervention: Intra-articular Hyalgan injections
Number of subjects: 38

Group type: COMPARATOR
Intervention: Arthroscopic washout
Number of subjects: 38
Study: 9895040

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo/expect alcohol
Number of subjects: 63
Study: 7984193

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 821

Group type: COMPARATOR
Intervention: Standard insertion procedures (Control)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Successful catheterization
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Needle passes
Number of subjects: 821
Study: 2603701

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 1177792

Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide dinitrate (Sorbidilat Retard)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30427251

Group type: COMPARATOR
Intervention: Cluster Set (CS) - 4 × [2 × 3], 30‐s intraset rest, 90‐s interset rest
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Traditional Set (TS) - 4 × 6, 2‐min interset rest
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Joint power produced at the hip during TS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Joint power produced at the hip during CS
Number of subjects: 8
Study: 28600158

Group type: EXPERIMENTAL
Intervention: WLM plus lorcaserin
Number of subjects: 182

Group type: COMPARATOR
Intervention: WLM plus placebo
Number of subjects: 182
Study: 26164694

Group type: EXPERIMENTAL
Intervention: Group prenatal care (Centering Pregnancy Plus [CP+])
Number of subjects: 984

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 984
Study: 22453307

Group type: EXPERIMENTAL
Intervention: Medical elastic compression stocking
Number of subjects: 88

Group type: COMPARATOR
Intervention: No stocking (control)
Number of subjects: 88
Study: 20552100

Group type: EXPERIMENTAL
Intervention: Fluoride exposure (Crest toothpaste 0.243% sodium fluoride and Equate rinse 0.05% sodium fluoride)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonfluoridated toothpaste (Tom's of Maine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (unused Ni-Ti wires)
Number of subjects: 100
Study: 19276493

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg bolus dose followed by 75 mg once daily)
Number of subjects: 0
Study: 16822130

Group type: EXPERIMENTAL
Intervention: Sequential effects in the Simon task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive conflict
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature integration account
Number of subjects: 0
Study: 12738811

Group type: EXPERIMENTAL
Intervention: SC‐51 (200 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10735263

Group type: EXPERIMENTAL
Intervention: Statistical concepts of significance and power used in determining sample size for trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials design.
Number of subjects: 0
Study: 1356467

Group type: EXPERIMENTAL
Intervention: Excision and primary suture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Excision and open packing
Number of subjects: 120
Study: 3874897

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic variceal obliteration using stainless steel coils followed by 50% glucose and Gelfoam
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Elective cases of transhepatic variceal obliteration
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 63
Study: 27532425

Group type: EXPERIMENTAL
Intervention: LEAP intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Psychoeducational control condition
Number of subjects: 80
Study: 29331169

Group type: EXPERIMENTAL
Intervention: 2‐min step‐in‐place test (fitness test)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no fitness testing)
Number of subjects: 33
Study: 27438754

Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control
Number of subjects: 343
Study: 24874481

Group type: EXPERIMENTAL
Intervention: Overexpression of TBLR1 in Hela and Siha cell lines
Number of subjects: 0

Group type: COMPARATOR
Intervention: RNAi-mediated knockdown of TBLR1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TBLR1 expression levels
Number of subjects: 0
Study: 23186118

Group type: EXPERIMENTAL
Intervention: School-led FRIENDS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Health-led FRIENDS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 41
Study: 20598608

Group type: EXPERIMENTAL
Intervention: Postprandial glucose excursions (AUC(ppg))
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Total daytime glucose concentrations (AUC(total))
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Percentage of glycaemia due to postprandial excursions (%(ppg))
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: HOMA‐B
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: ΔI30/ΔG30 ratio
Number of subjects: 973
Study: 17122432

Group type: EXPERIMENTAL
Intervention: Neutral wrist splinting
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Extended wrist splinting
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 63
Study: 16132802

Group type: COMPARATOR
Intervention: Dietary supplements
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dietary fat
Number of subjects: 250

Group type: COMPARATOR
Intervention: Highest quartile of beef and pork intake
Number of subjects: 250

Group type: COMPARATOR
Intervention: Fat intake
Number of subjects: 250
Study: 12097764

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 235

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice a day for 10 days
Number of subjects: 235
Study: 10023111

Group type: EXPERIMENTAL
Intervention: 1,000 mg lysine-acetylsalicylic acid i.v.
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.5 mg ergotamine s.c.
Number of subjects: 56
Study: 7478833

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.6 mg/kg/d (dexamethasone base 0.5 mg/kg/d)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 209
Study: 1926256

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 39
Study: 7049957

Group type: EXPERIMENTAL
Intervention: Erythromycin (2 X 1 g daily per os)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxicillin (3 X 0.75 g daily per os)
Number of subjects: 60
Study: 31134323

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (60 mg/m2)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (25 mg/m2)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic analysis (oral: n=222; intravenous: n=111)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Reference European data set (oral: 80 mg/m2; intravenous: 30 mg/m2)
Number of subjects: 222
Study: 28237295

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate/low-GI diet (LGI, n = 31)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate/high-GI diet (HGI, n = 30)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-fat diet (LF, n = 26)
Number of subjects: 87
Study: 27113967

Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Maximum urethral closure pressure
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Urinary NTx
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Vitamin D2 plus D3
Number of subjects: 427

Group type: COMPARATOR
Intervention: TOMUS subjects
Number of subjects: 427

Group type: COMPARATOR
Intervention: ValUE subjects
Number of subjects: 427
Study: 23624466

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention programme targeting physical activity, sedentary and dietary behaviours over 20 months
Number of subjects: 1324
Study: 22386472

Group type: EXPERIMENTAL
Intervention: 1 mg ABT-894 twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 2 mg ABT-894 twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 4 mg ABT-894 twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 6 mg ABT-894 twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine once per day (Study 1)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 20201945

Group type: EXPERIMENTAL
Intervention: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2) with concurrent heparin prophylaxis
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Re-exposure to Asparaginase
Number of subjects: 1824
Study: 17661342

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented intervention delivered on 3 occasions over 9 to 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study: 15569860

Group type: EXPERIMENTAL
Intervention: Folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 12101076

Group type: EXPERIMENTAL
Intervention: Early dexamethasone therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 20
Study: 10189536

Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 40/40 micrograms/kg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 80/40 micrograms/kg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 80/60 micrograms/kg
Number of subjects: 223

Group type: COMPARATOR
Intervention: Intensified insulin therapy alone (placebo)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhIGF‐I/insulin cotherapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Higher doses of rhIGF‐I
Number of subjects: 223
Study: 7772362

Group type: EXPERIMENTAL
Intervention: TIVA with midazolam-alfentanil reversed with flumazenil (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: TIVA with midazolam-alfentanil without reversal (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neurolept anesthesia with thiopental sodium, droperidol, fentanyl, and N2O (Group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neurolept anesthesia (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 2271083

Group type: EXPERIMENTAL
Intervention: Triple therapy (low-dose azathioprine, cyclosporin, methylprednisolone) continued (group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aza and CyA (group B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aza and MP (group C)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CyA and MP (group D)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Graft survival rates
Number of subjects: 128

Group type: COMPARATOR
Intervention: Patient survival rates
Number of subjects: 128
Study: 76398

Group type: EXPERIMENTAL
Intervention: 20% podophyllin
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 8% podophyllotoxin
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 8% colchicine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 227
Study: 31633262

Group type: EXPERIMENTAL
Intervention: Fructans (40g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fructose (40g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose (as placebo)
Number of subjects: 20
Study: 31894036

Group type: COMPARATOR
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 86
Study: 27492741

Group type: EXPERIMENTAL
Intervention: Repetitive intracutaneous injections with local anesthetics and steroids
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 93
Study: 25878175

Group type: EXPERIMENTAL
Intervention: Perampanel 4-12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23151354

Group type: EXPERIMENTAL
Intervention: Two green kiwifruits per day plus healthy diet
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy diet alone
Number of subjects: 85
Study: 21899566

Group type: EXPERIMENTAL
Intervention: 1% NaOCl (30 min) + 17% EDTA (5 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% EDTA (30 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 24% EDTA gel (30 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2% CHX gel (30 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1% NaOCl (30 min)
Number of subjects: 100
Study: 19014354

Group type: EXPERIMENTAL
Intervention: Desferroxamine infusion for 8 hours
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desferroxamine infusion
Number of subjects: 15
Study: 17503749

Group type: EXPERIMENTAL
Intervention: DNAaemia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Antigenaemia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 200
Study: 15343531

Group type: EXPERIMENTAL
Intervention: General anesthesia plus femoral nerve block (FNB) with 30 mL of 0.5% bupivacaine with epinephrine 1:200,000
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia plus femoral nerve block (FNB) with 30 mL of preservative-free saline
Number of subjects: 40
Study: 11451621

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days followed by chlormadinone acetate for 5 days
Number of subjects: 25
Study: 9511844

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Geriatric Oral Health Assessment Index (GOHAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-reported need for dental treatment
Number of subjects: 0
Study: 7872725

Group type: EXPERIMENTAL
Intervention: CA 19.9 > 37 U/ml
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEA > 5 ng/ml
Number of subjects: 150
Study: 3258994

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Voluntary Exercise Group
Number of subjects: 20
Study: 29885153

Group type: EXPERIMENTAL
Intervention: Specialist model of SBIRT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Generalist model of SBIRT
Number of subjects: 7
Study: 27185699

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg (P150)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg (P75)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Diazepam 5 mg (D5)
Number of subjects: 97
Study: 24725276

Group type: EXPERIMENTAL
Intervention: Inspiratory respiratory training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Expiratory respiratory training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham respiratory training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 100
Study: 22109683

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 57
Study: 19531931

Group type: EXPERIMENTAL
Intervention: ProSorb-D 12.5 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DPSGC 50 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Diclofenac potassium 50 mg tablet
Number of subjects: 53
Study: 18543381

Group type: EXPERIMENTAL
Intervention: Medical Qigong (MQ) program for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 30
Study: 15967914

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream, 40-g/d dosage
Number of subjects: 341

Group type: COMPARATOR
Intervention: Oral corticosteroids, 0.5 or 1.0 mg/kg per day depending on extent of BP
Number of subjects: 341
Study: 12071371

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances and initial archwire placement
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 18
Study: 10332663

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-carbohydrate diet (40%)
Number of subjects: 9
Study: 8738944

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 111
Study: 1902410

Group type: EXPERIMENTAL
Intervention: ponalrestat (two 300 mg tablets daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 55
Study: 6176796

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31189759

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level I with low HDL-C (＜40 mg/dL for men; ＜50 mg/dL for women)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level II with high HDL-C (≥ 40 mg/dL for men; ≥ 50 mg/dL for women)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level III with high HDL-C and low triglycerides (＜150 mg/dL)
Number of subjects: 3640

Group type: COMPARATOR
Intervention: No lipid-modifying therapy (LT) prescribed (level 0)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level I
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level II
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level III
Number of subjects: 3640
Study: 31437816

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 176250

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors
Number of subjects: 176250

Group type: EXPERIMENTAL
Intervention: GLP1 analogs
Number of subjects: 176250

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 176250
Study: 29088237

Group type: EXPERIMENTAL
Intervention: Current weekend allied health service (including physical therapy, occupational therapy, speech therapy, dietetics, social work, and allied health assistant services)
Number of subjects: 14834

Group type: COMPARATOR
Intervention: No weekend allied health service
Number of subjects: 14834

Group type: EXPERIMENTAL
Intervention: Newly developed weekend allied health service
Number of subjects: 14834